{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.117.1.7.1.134","meta":{"source":"https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.117.1.7.1.134/expansion"},"url":"http://vsac.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134","version":"eCQM Update 2020-05-07","name":"OralFactorXaInhibitorForVTEProphylaxisOrVTETreatment","title":"Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment","status":"active","date":"2019-03-05","description":"(Clinical Focus: This value set contains concepts that represent oral factor Xa inhibitors indicated for venous thromboembolism (VTE) prophylaxis and treatment. ),(Data Element Scope: This value set may use the Quality Data Model (QDM) category related to Medication. The intent of this data element is to identify patients who receive oral factor Xa inhibitors for VTE prophylaxis. ),(Inclusion Criteria: Includes only relevant concepts associated with oral forms of factor Xa inhibitors.),(Exclusion Criteria: Excludes other dose forms of factor Xa inhibitors.)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"2020-01","concept":[{"code":"1114198","display":"rivaroxaban 10 MG Oral Tablet"},{"code":"1232082","display":"rivaroxaban 15 MG Oral Tablet"},{"code":"1232086","display":"rivaroxaban 20 MG Oral Tablet"},{"code":"1364435","display":"apixaban 2.5 MG Oral Tablet"},{"code":"1364445","display":"apixaban 5 MG Oral Tablet"},{"code":"1549682","display":"{42 (rivaroxaban 15 MG Oral Tablet) / 9 (rivaroxaban 20 MG Oral Tablet) } Pack"},{"code":"1599543","display":"edoxaban 15 MG Oral Tablet"},{"code":"1599551","display":"edoxaban 30 MG Oral Tablet"},{"code":"1599555","display":"edoxaban 60 MG Oral Tablet"},{"code":"1927856","display":"betrixaban 40 MG Oral Capsule"},{"code":"1927864","display":"betrixaban 80 MG Oral Capsule"},{"code":"1992427","display":"{74 (apixaban 5 MG Oral Tablet) } Pack"},{"code":"2059015","display":"rivaroxaban 2.5 MG Oral Tablet"}]}]}}